Evidence map›Paper›PMID 22124578›Full record

ArticleBreast cancer research and treatment2012

Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer.

Juan P Cerliani, Silvia I Vanzulli, Cecilia Pérez Piñero, María C Bottino, Ana Sahores, Myriam Nuñez, Romina Varchetta, Rubén Martins, Eduardo Zeitlin, Stephen M Hewitt and 3 more

Open access · greenAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 4 countries.

Juan P CerlianiInstitute of Experimental Biology and Medicine, CONICET, Vuelta de Obligado 2490, C1428ADN Buenos Aires, Argentina.
Silvia I Vanzulli
Cecilia Pérez Piñero
María C Bottino
Ana Sahores
Myriam Nuñez
Romina Varchetta
Rubén Martins
Eduardo Zeitlin
Stephen M Hewitt
Alfredo A Molinolo
Claudia Lanari
Caroline A Lamb
Consejo Nacional de Investigaciones Científicas y Técnicas · ARPoliclinica Metropolitana · VEExperimental Medicine and Biology Institute · ARNational Cancer Institute · USNational Institutes of Health · USUniversity of Buenos Aires · AR

Funding

Tissue Array Research ProgramZICBC010923 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HEWITT, STEPHEN · 2009 to 2014
$4.7M
Intramural NIH HHS ZIC BC010923
6 · The paper itself

Abstract

Fibroblast growth factor receptors (FGFRs) are tyrosine kinase receptors which have been implicated in breast cancer. The aim of this study was to evaluate FGFR-1, -2, -3, and -4 protein expressions in normal murine mammary gland development, and in murine and human breast carcinomas. Using immunohistochemistry and Western blot, we report a hormonal regulation of FGFR during postnatal mammary gland development. Progestin treatment of adult virgin mammary glands resulted in changes in localization of FGFR-3 from the cytoplasm to the nucleus, while treatment with 17-β-estradiol induced changes in the expressions and/or localizations of FGFR-2 and -3. In murine mammary carcinomas showing different degrees of hormone dependence, we found progestin-induced increased expressions, mainly of FGFR-2 and -3. These receptors were constitutively activated in hormone-independent variants. We studied three luminal human breast cancer cell lines growing as xenografts, which particularly expressed FGFR-2 and -3, suggesting a correlation between hormonal status and FGFR expression. Most importantly, in breast cancer samples from 58 patients, we found a strong association (P < 0.01; Spearman correlation) between FGFR-2 and -3 expressions and a weaker correlation of each receptor with estrogen receptor expression. FGFR-4 correlated with c-erbB2 over expression. We conclude that FGFR-2 and -3 may be mechanistically linked and can be potential targets for treatment of estrogen receptor-positive breast cancer patients.

Indexed as

AdultAgedAnimalsBreast NeoplasmsCell Line, TumorCluster AnalysisFemaleGene Expression ProfilingHumansMammary Glands, AnimalMiceMice, Inbred BALB CMice, Inbred NODMice, NudeMice, SCIDMiddle AgedReceptor, Fibroblast Growth Factor, Type 2Receptor, Fibroblast Growth Factor, Type 3

Identifiers

PMID22124578
PMCPMC7511987
OpenAlexW2072705586

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.